정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 576 | Suspended | Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia | SARS-CoV-2 Infection | Drug: S-1226 | Phase 2 | SolAeroMed Inc. | INDUSTRY | 30 | All | 18 Years ~ 80 Years | Alberta Lung Function, Calgary, Alberta, Canada |
| 575 | Not yet recruiting | Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. | COVID-19 Respiratory Infection | Drug: S-1226 (8%) Other: Placebo |
Phase 2 | SolAeroMed Inc. | INDUSTRY | 48 | All | 18 Years ~ 80 Years | |
| 574 | Not yet recruiting | Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia | COVID-19 Pneumonia | Drug: Uproleselan | Phase 2 | Lena Napolitano, MD, GlycoMimetics Incorporated | OTHER | 15 | All | 18 Years ~ 75 Years | The University of Michigan, Ann Arbor, Michigan, United States |
| 573 | Active, not recruiting | Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. | SARS-CoV 2 | Biological: Intramuscular Vaccine | Phase 1 | Medicago | INDUSTRY | 180 | All | 18 Years ~ 55 Years | Syneos Health, Montreal, Quebec, Canada Syneos Health, Quebec, Quebec, Canada |
| 572 | Recruiting | Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 | SARS-CoV 2 | Biological: INO-4800 Device: CELLECTRA® 2000 Other: Saline-sodium citrate (SSC) buffer |
Phase 2 | International Vaccine Institute, Coalition for Epidemic Preparedness Innovations, Inovio Pharmaceuticals | OTHER | 160 | All | 19 Years ~ 64 Years | Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of Seoul National University Hospital, Seoul, Korea, Republic of |
| 571 | Active, not recruiting | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Coronavirus Infection | Drug: INO-4800 Device: CELLECTRA® 2000 |
Phase 1 | Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations | INDUSTRY | 120 | All | 18 Years | Central Kentucky Research Associates, Lexington, Kentucky, United States Center for Pharmaceutical Research, Kansas City, Missouri, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States |
| 570 | Recruiting | Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 | Covid19 | Biological: MVA-SARS-2-ST Biological: Licensed COVID-19 vaccine |
Phase 2 | Universitatsklinikum Hamburg-Eppendorf, German Center for Infection Research, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, IDT Biologika, Clinical Trial Center North (CTC North GmbH & Co. KG) | OTHER | 240 | All | 18 Years | CTC North, Hamburg, Germany |